PepGen Inc.
PepGen is a clinical-stage biotechnology company developing oligonucleotide therapeutics for severe neuromuscular and neurologic diseases. Its Enhanced Delivery Oligonucleotide platform uses cell-penetrating peptides conjugated to oligonucleotide cargo to promote cellular uptake and delivery to the nucleus. PepGen’s lead product candidate, PGN-EDODM1, is being developed for myotonic dystrophy type 1. It is designed to bind expanded repeats in DMPK messenger RNA and release the RNA-binding protein MBNL1, with the aim of correcting disease-related RNA splicing. The candidate uses a peptide-conjugated morpholino oligonucleotide. PepGen’s clinical development program for PGN-EDODM1 includes the completed Phase 1 FREEDOM study, the Phase 2 FREEDOM2 study and the FREEDOM-OLE open-label extension study. The company also develops its EDO platform for potential use with other oligonucleotide cargos. PepGen is headquartered in Boston, Massachusetts.
No SEC Form 4 filings for $PEPG in the last 30 days.
See all $PEPG insider activity →PepGen (PEPG) reported a Q3 GAAP EPS of -$0.28, missing estimates by $0.01. The company had $104.8M in cash and equivalents as of September 30, 2026, and expects this to fund operations into 2028.
PepGen Inc. (PEPG) filed an SEC Form 8-K — Results of Operations and Financial Condition. PepGen Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights – Positive FREEDOM2-DM1 10 mg/kg cohort results demonstrated highest reported splicing correction and improvements across multiple functional measures – – 12.5 mg/kg FREEDOM2-DM1 cohort fully enro
PepGen (PEPG) shares rose 100% premarket after reporting new mid-stage trial data for PGN-EDODM1, a treatment for myotonic dystrophy type 1, a rare genetic muscle disorder.
Over the past 7 days, AlphAI's AI scored 10 news stories mentioning PEPG (PepGen Inc.). Coverage has skewed bullish: 8 bullish, 0 neutral, and 2 bearish.
Recent PEPG coverage spans earnings, financial news and market movers.
The miss may trigger modest sell pressure as investors reassess near‑term profitability.
Positive trial data and solid cash position suggest near‑term upside.
Positive trial data is expected to drive strong buying pressure.
The widened loss and lack of revenue suggest continued cash burn, likely pressuring the stock lower.
Near-term catalyst is the November readout for the 10 mg/kg FREEDOM2 cohort, following DSMB-approved escalation to 12.5 mg/kg.
AlphAI scores every news story that mentions PEPG with an AI model for sentiment and relevance, and aggregates insider trades from PepGen Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
PepGen (PEPG) reported a Q3 GAAP EPS of -$0.28, missing estimates by $0.01. The company had $104.8M in cash and equivalents as of September 30, 2026, and expects this to fund operations into 2028.
PepGen Inc. (PEPG) filed an SEC Form 8-K — Results of Operations and Financial Condition. PepGen Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights – Positive FREEDOM2-DM1 10 mg/kg cohort results demonstrated highest reported splicing correction and improvements across multiple functional measures – – 12.5 mg/kg FREEDOM2-DM1 cohort fully enro
PepGen (PEPG) shares rose 100% premarket after reporting new mid-stage trial data for PGN-EDODM1, a treatment for myotonic dystrophy type 1, a rare genetic muscle disorder.
PepGen reported no revenue and a net loss of $19.39M for 3Q 2026, with higher R&D and clinical trial costs. EPS improved to ($0.28) from ($0.52) YoY. FREEDOM2 trial showed 46.5% splicing correction at 10 mg/kg, but remains on partial clinical hold. PepGen enrolled 19 participants in FREEDOM-OLE and discontinued DMD-related R&D.
PepGen Inc. (PEPG) filed an SEC Form 8-K — Results of Operations and Financial Condition. PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights – DSMB recommends advancement of PGN-EDODM1 into the highest dose cohort in the FREEDOM2-DM1 study, as well as FREEDOM-OLE dose escalation from 5 mg/kg to 10 mg/kg – – 10 mg/kg FREEDOM2-DM1 cohor
PepGen Inc. (PEPG) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001835597 0001835597 2026-06-18 2026-06-18 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18,
Kasraian Kasra (Chief Technical Officer) sold 1,233 shares of PepGen Inc. (PEPG) at $1.41 on 2026-05-21 under a Rule 10b5-1 trading plan.
This article discusses the recent 14.3% drop in PepGen (PEPG) stock over the past four weeks. It suggests that despite this downturn, the stock might be poised for a trend reversal. The content will likely delve into technical or fundamental reasons for this potential change in trajectory.
H.C. Wainwright analyst Ananda Ghosh maintained a Buy rating on PepGen Inc. with a $20.00 price target. Ghosh believes PepGen's DM1 program is de-risked due to stronger underlying biology observed in treated patients, despite a modest average splicing correction skewed by an anomalous patient. The analyst anticipates significant upside from higher-dose cohorts, expecting materially higher splicing correction which could serve as a key value inflection point for the stock.
PepGen Ltd (NASDAQ:PEPG) shares dropped 44% after-hours following disappointing Phase 2 trial results for its myotonic dystrophy type 1 treatment, PGN-EDODM1. The drug showed an average splicing correction of 7.3% compared to placebo, with an outlier patient significantly impacting the overall mean. Despite the setback, the company plans to report data from a higher dose cohort in late 2026 and has sufficient funding into mid-2027.
